<?xml version='1.0' encoding='utf-8'?>
<document id="22850102"><sentence text="[Therapeutic drug monitoring of lacosamide]."><entity charOffset="32-43" id="DDI-PubMed.22850102.s1.e0" text="lacosamide]" /></sentence><sentence text="Lacosamide is a third generation antiepileptic drug, available in France since 2008"><entity charOffset="0-10" id="DDI-PubMed.22850102.s2.e0" text="Lacosamide" /></sentence><sentence text=" It is indicated in combination therapy for the treatment of inadequately controlled focal seizures, from the age of 16" /><sentence text=" The bioavailability of lacosamide is 100% and is unaffected by food intake; protein binding is low; it is metabolized by CYP2C19 into inactive O-desmethyl lacosamide"><entity charOffset="24-34" id="DDI-PubMed.22850102.s4.e0" text="lacosamide" /><entity charOffset="144-166" id="DDI-PubMed.22850102.s4.e1" text="O-desmethyl lacosamide" /><pair ddi="false" e1="DDI-PubMed.22850102.s4.e0" e2="DDI-PubMed.22850102.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22850102.s4.e0" e2="DDI-PubMed.22850102.s4.e1" /></sentence><sentence text=" It does not inhibit or induce cytochromes; the elimination is renal with a half-life of approximately 13 h" /><sentence text=" The relationship between dose and plasma concentration is established, but there does not appear to be any clear relationship between concentration and efficacy" /><sentence text=" However, the main side effects are concentration dependent" /><sentence text=" The potential for drug-drug interaction of lacosamide is low and variability between individuals is minimal"><entity charOffset="44-54" id="DDI-PubMed.22850102.s8.e0" text="lacosamide" /></sentence><sentence text=" Accordingly, the level of evidence for the therapeutic drug monitoring has been estimated at &quot;probably of no use&quot;" /><sentence text="" /></document>